Investigating secular trends in the survival of melanoma patients
Research type
Research Study
Full title
Investigating secular trends in the survival of melanoma patients in England
IRAS ID
266478
Contact name
Beth Nordstrom
Contact email
Sponsor organisation
Evidera (on behalf of Bristol-Myers Squibb)
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This study aims to evaluate how long patients with a form of skin cancer, malignant melanoma, survive after being diagnosed, and to study whether this has changed over time. The specific objectives of this study are: (1) To describe the demographic and clinical characteristics of patients diagnosed with malignant melanoma, (2)To describe trends in one-year survival over time among malignant melanoma patients, both overall and separately by disease stage and socioeconomic status, and (3)To model changes in survival over time among these patients.
We will use cancer registration data from Public Health England to address our study objectives. Specifically, we will analyse the data to describe patient characteristics and calculate time to death. We will also calculate a measure called ‘relative survival’, which is an estimate of how the survival among cancer patients compares to that in the general population. This is valuable because not all patients who die may die due to their cancer, and this statistic takes that into account.
REC name
London - Stanmore Research Ethics Committee
REC reference
19/LO/1094
Date of REC Opinion
5 Jul 2019
REC opinion
Further Information Favourable Opinion